ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,813.70
0.13%
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs Yen
157.2625
0.00%
Brent Oil
80.975
-0.39%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTAW)

  7. Pasithea Therapeutics Corporation (KTTAW) ニュース

KTTAW

Pasithea Therapeutics (KTTAW)

Pasithea Therapeutics Corporation
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:KTTAW
日付受信時刻ニュースソース見出しコード企業名
2024/05/2822 : 05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAWPasithea Therapeutics Corporation
2024/05/2822 : 00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTTAWPasithea Therapeutics Corporation
2024/05/2819 : 59GlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
2024/05/1506 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAWPasithea Therapeutics Corporation
2024/04/2920 : 59GlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
2024/04/2420 : 59GlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAWPasithea Therapeutics Corporation
2024/02/1321 : 59GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
2024/01/0821 : 59GlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAWPasithea Therapeutics Corporation
2024/01/0222 : 35GlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/12/2907 : 00GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAWPasithea Therapeutics Corporation
2023/12/2007 : 19GlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/12/1122 : 01GlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/11/3006 : 27GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/11/2921 : 59GlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/11/0921 : 59GlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/09/1421 : 30GlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Final Results of Tender OfferNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/09/0805 : 14GlobeNewswire Inc.Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/08/0120 : 59GlobeNewswire Inc.Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/07/2021 : 43GlobeNewswire Inc.Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/07/2021 : 40GlobeNewswire Inc.Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.NASDAQ:KTTAWPasithea Therapeutics Corporation
2023/06/3022 : 28GlobeNewswire Inc.Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/06/2921 : 29GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
2023/06/0705 : 30GlobeNewswire Inc.Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.NASDAQ:KTTAWPasithea Therapeutics Corporation
2023/06/0120 : 57GlobeNewswire Inc.Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/05/0321 : 26GlobeNewswire Inc.Pasithea Therapeutics to Participate in EF Hutton Inaugural Global ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/03/0222 : 00GlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/02/2322 : 00GlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)NASDAQ:KTTAWPasithea Therapeutics Corporation
2023/02/1621 : 30GlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine AwardNASDAQ:KTTAWPasithea Therapeutics Corporation
2023/01/1822 : 00GlobeNewswire Inc.Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
2022/12/1507 : 17GlobeNewswire Inc.Majority of Stockholders Support Pasithea Directors at Special MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:KTTAW

最近閲覧した銘柄

USOTC
BKTRF
Black Rock Mining (PK)
UPBT
NUKRW
NuCypher
BOV
PETRF262
PETRF262 Ex:22,2
BIT
P201C5
NLBNPIT201C5 20240621 19
ASX
CARRA
Carsales.com
EU
BE0002264332
Atenor 3.75% 11oct2024
LSE
87RY
Municplty 27
BOV
CEEB6F
COELBA PNB
BIT
P1XIN9
NLBNPIT1XIN9 20240920 11
BIT
I09257
Intesa Sanpaolo
BIT
P1YJC8
NLBNPIT1YJC8 20991231 55...
BIT
P20JI5
NLBNPIT20JI5 20991231 72...
BIT
MAPS
Maps
EU
XS2014372291
Cartesian Residential Mo...
ASX
AVJ
Avjennings
LSE
82TO
Arran 2.bb56s
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有